Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Oct 15;100(8):2133–2137. doi: 10.1172/JCI119748

Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.

W A Franklin 1, A F Gazdar 1, J Haney 1, I I Wistuba 1, F G La Rosa 1, T Kennedy 1, D M Ritchey 1, Y E Miller 1
PMCID: PMC508406  PMID: 9329980

Abstract

Individuals with one aerodigestive tract malignancy have a high incidence of second primary aerodigestive tumors. The mechanism for this field effect has not been determined. We studied an individual with widespread dysplastic changes in the respiratory epithelium but no overt carcinoma. The entire tracheobronchial tree obtained at autopsy was embedded in paraffin, and bronchial epithelial cells were isolated by microdissection. DNA extracted from the microdissected cells was analyzed for point mutations in the p53 tumor suppressor gene. A single, identical point mutation consisting of a G:C to T:A transversion in codon 245 was identified in bronchial epithelium from 7 of 10 sites in both lungs. Epithelium at sites containing the p53 mutation was morphologically abnormal, exhibiting squamous metaplasia and mild to moderate atypia. No invasive tumor was found in the tracheobronchial tree or any other location. Cells from peripheral blood, kidney, liver, and lymph node exhibited no abnormality in the p53 gene. The widespread presence of a single somatic p53 point mutation in the bronchi of a smoker suggests that a single progenitor bronchial epithelial clone may expand to populate broad areas of the bronchial mucosa-a novel mechanism for field carcinogenesis in the respiratory epithelium that may be of importance in assessing individuals for risk of a second primary tumor as well as in devising effective strategies for chemoprevention of lung cancer.

Full Text

The Full Text of this article is available as a PDF (206.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antakli T., Schaefer R. F., Rutherford J. E., Read R. C. Second primary lung cancer. Ann Thorac Surg. 1995 Apr;59(4):863–867. doi: 10.1016/0003-4975(95)00067-u. [DOI] [PubMed] [Google Scholar]
  2. Bennett W. P., Colby T. V., Travis W. D., Borkowski A., Jones R. T., Lane D. P., Metcalf R. A., Samet J. M., Takeshima Y., Gu J. R. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 1993 Oct 15;53(20):4817–4822. [PubMed] [Google Scholar]
  3. Boers J. E., ten Velde G. P., Thunnissen F. B. P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Am J Respir Crit Care Med. 1996 Jan;153(1):411–416. doi: 10.1164/ajrccm.153.1.8542151. [DOI] [PubMed] [Google Scholar]
  4. Cho K. R., Vogelstein B. Genetic alterations in the adenoma--carcinoma sequence. Cancer. 1992 Sep 15;70(6 Suppl):1727–1731. doi: 10.1002/1097-0142(19920915)70:4+<1727::aid-cncr2820701613>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  5. Chung G. T., Sundaresan V., Hasleton P., Rudd R., Taylor R., Rabbitts P. H. Clonal evolution of lung tumors. Cancer Res. 1996 Apr 1;56(7):1609–1614. [PubMed] [Google Scholar]
  6. Chung G. T., Sundaresan V., Hasleton P., Rudd R., Taylor R., Rabbitts P. H. Sequential molecular genetic changes in lung cancer development. Oncogene. 1995 Dec 21;11(12):2591–2598. [PubMed] [Google Scholar]
  7. Deschamps C., Pairolero P. C., Trastek V. F., Payne W. S. Multiple primary lung cancers. Results of surgical treatment. J Thorac Cardiovasc Surg. 1990 May;99(5):769–778. [PubMed] [Google Scholar]
  8. Dutrillaux B. Pathways of chromosome alteration in human epithelial cancers. Adv Cancer Res. 1995;67:59–82. doi: 10.1016/s0065-230x(08)60710-1. [DOI] [PubMed] [Google Scholar]
  9. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  10. Ferguson M. K., DeMeester T. R., DesLauriers J., Little A. G., Piraux M., Golomb H. Diagnosis and management of synchronous lung cancers. J Thorac Cardiovasc Surg. 1985 Mar;89(3):378–385. [PubMed] [Google Scholar]
  11. Ferguson M. K. Synchronous primary lung cancers. Chest. 1993 Apr;103(4 Suppl):398S–400S. doi: 10.1378/chest.103.4_supplement.398s. [DOI] [PubMed] [Google Scholar]
  12. Fontanini G., Vignati S., Bigini D., Merlo G. R., Ribecchini A., Angeletti C. A., Basolo F., Pingitore R., Bevilacqua G. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol. 1994 Sep;174(1):23–31. doi: 10.1002/path.1711740105. [DOI] [PubMed] [Google Scholar]
  13. Frebourg T., Sadelain M., Ng Y. S., Kassel J., Friend S. H. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res. 1994 Feb 15;54(4):878–881. [PubMed] [Google Scholar]
  14. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  15. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 1992 Nov 13;71(4):543–546. doi: 10.1016/0092-8674(92)90586-2. [DOI] [PubMed] [Google Scholar]
  16. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature. 1987 Sep 17;329(6136):219–222. doi: 10.1038/329219a0. [DOI] [PubMed] [Google Scholar]
  17. Heyne K. H., Lippman S. M., Lee J. J., Lee J. S., Hong W. K. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol. 1992 Oct;10(10):1519–1524. doi: 10.1200/JCO.1992.10.10.1519. [DOI] [PubMed] [Google Scholar]
  18. Hung J., Kishimoto Y., Sugio K., Virmani A., McIntire D. D., Minna J. D., Gazdar A. F. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA. 1995 Feb 15;273(7):558–563. [PubMed] [Google Scholar]
  19. Johnson B. E., Ihde D. C., Matthews M. J., Bunn P. A., Zabell A., Makuch R. W., Johnston-Early A., Cohen M. H., Glatstein E., Minna J. D. Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer. Am J Med. 1986 Jun;80(6):1103–1110. doi: 10.1016/0002-9343(86)90672-8. [DOI] [PubMed] [Google Scholar]
  20. Johnson B. E., Linnoila R. I., Williams J. P., Venzon D. J., Okunieff P., Anderson G. B., Richardson G. E. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol. 1995 Jan;13(1):101–111. doi: 10.1200/JCO.1995.13.1.101. [DOI] [PubMed] [Google Scholar]
  21. Kishimoto Y., Sugio K., Hung J. Y., Virmani A. K., McIntire D. D., Minna J. D., Gazdar A. F. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst. 1995 Aug 16;87(16):1224–1229. doi: 10.1093/jnci/87.16.1224. [DOI] [PubMed] [Google Scholar]
  22. Knudson A. G. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10914–10921. doi: 10.1073/pnas.90.23.10914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  24. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  25. Mao L., Lee J. S., Kurie J. M., Fan Y. H., Lippman S. M., Lee J. J., Ro J. Y., Broxson A., Yu R., Morice R. C. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst. 1997 Jun 18;89(12):857–862. doi: 10.1093/jnci/89.12.857. [DOI] [PubMed] [Google Scholar]
  26. Martini N., Bains M. S., Burt M. E., Zakowski M. F., McCormack P., Rusch V. W., Ginsberg R. J. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995 Jan;109(1):120–129. doi: 10.1016/S0022-5223(95)70427-2. [DOI] [PubMed] [Google Scholar]
  27. Mathisen D. J., Jensik R. J., Faber L. P., Kittle C. F. Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg. 1984 Oct;88(4):502–510. [PubMed] [Google Scholar]
  28. Milner J., Medcalf E. A., Cook A. C. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol. 1991 Jan;11(1):12–19. doi: 10.1128/mcb.11.1.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Phelps R. M., Johnson B. E., Ihde D. C., Gazdar A. F., Carbone D. P., McClintock P. R., Linnoila R. I., Matthews M. J., Bunn P. A., Jr, Carney D. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996;24:32–91. doi: 10.1002/jcb.240630505. [DOI] [PubMed] [Google Scholar]
  30. Pommier R. F., Vetto J. T., Lee J. T., Johnston K. M. Synchronous non-small cell lung cancers. Am J Surg. 1996 May;171(5):521–524. doi: 10.1016/S0002-9610(96)00019-0. [DOI] [PubMed] [Google Scholar]
  31. Rusch V., Klimstra D., Linkov I., Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res. 1995 Mar 15;55(6):1365–1372. [PubMed] [Google Scholar]
  32. SLAUGHTER D. P., SOUTHWICK H. W., SMEJKAL W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953 Sep;6(5):963–968. doi: 10.1002/1097-0142(195309)6:5<963::aid-cncr2820060515>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  33. Saccomanno G., Archer V. E., Auerbach O., Saunders R. P., Brennan L. M. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer. 1974 Jan;33(1):256–270. doi: 10.1002/1097-0142(197401)33:1<256::aid-cncr2820330139>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  34. Sakamoto H., Lewis M. S., Kodama H., Appella E., Sakaguchi K. Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8974–8978. doi: 10.1073/pnas.91.19.8974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sheppard D. Dominant negative mutants: tools for the study of protein function in vitro and in vivo. Am J Respir Cell Mol Biol. 1994 Jul;11(1):1–6. doi: 10.1165/ajrcmb.11.1.8018332. [DOI] [PubMed] [Google Scholar]
  36. Sidransky D., Frost P., Von Eschenbach A., Oyasu R., Preisinger A. C., Vogelstein B. Clonal origin bladder cancer. N Engl J Med. 1992 Mar 12;326(11):737–740. doi: 10.1056/NEJM199203123261104. [DOI] [PubMed] [Google Scholar]
  37. Soto D., Sukumar S. Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. PCR Methods Appl. 1992 Aug;2(1):96–98. doi: 10.1101/gr.2.1.96. [DOI] [PubMed] [Google Scholar]
  38. Sozzi G., Miozzo M., Donghi R., Pilotti S., Cariani C. T., Pastorino U., Della Porta G., Pierotti M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992 Nov 1;52(21):6079–6082. [PubMed] [Google Scholar]
  39. Sozzi G., Miozzo M., Pastorino U., Pilotti S., Donghi R., Giarola M., De Gregorio L., Manenti G., Radice P., Minoletti F. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res. 1995 Jan 1;55(1):135–140. [PubMed] [Google Scholar]
  40. Strauss B. S. The 'A rule' of mutagen specificity: a consequence of DNA polymerase bypass of non-instructional lesions? Bioessays. 1991 Feb;13(2):79–84. doi: 10.1002/bies.950130206. [DOI] [PubMed] [Google Scholar]
  41. Stürzbecher H. W., Brain R., Addison C., Rudge K., Remm M., Grimaldi M., Keenan E., Jenkins J. R. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene. 1992 Aug;7(8):1513–1523. [PubMed] [Google Scholar]
  42. Sundaresan V., Ganly P., Hasleton P., Rudd R., Sinha G., Bleehen N. M., Rabbitts P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene. 1992 Oct;7(10):1989–1997. [PubMed] [Google Scholar]
  43. Thomas P., Rubinstein L. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1990 Feb;49(2):242–247. doi: 10.1016/0003-4975(90)90145-v. [DOI] [PubMed] [Google Scholar]
  44. Vogelstein B., Kinzler K. W. The multistep nature of cancer. Trends Genet. 1993 Apr;9(4):138–141. doi: 10.1016/0168-9525(93)90209-z. [DOI] [PubMed] [Google Scholar]
  45. Walker C., Dixon G. R., Myskow M. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol. 1995 Jul;176(3):319–320. doi: 10.1002/path.1711760314. [DOI] [PubMed] [Google Scholar]
  46. Wang P., Reed M., Wang Y., Mayr G., Stenger J. E., Anderson M. E., Schwedes J. F., Tegtmeyer P. p53 domains: structure, oligomerization, and transformation. Mol Cell Biol. 1994 Aug;14(8):5182–5191. doi: 10.1128/mcb.14.8.5182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wu S. C., Lin Z. Q., Xu C. W., Koo K. S., Huang O. L., Xie D. Q. Multiple primary lung cancers. Chest. 1987 Nov;92(5):892–896. doi: 10.1378/chest.92.5.892. [DOI] [PubMed] [Google Scholar]
  48. Yuspa S. H., Poirier M. C. Chemical carcinogenesis: from animal models to molecular models in one decade. Adv Cancer Res. 1988;50:25–70. doi: 10.1016/s0065-230x(08)60434-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES